-
E-mail
willnano@163.com
-
Phone
18550201458
-
Address
3rd Floor, North Building A1, Biological Nanotechnology Park, No. 218 Xinghu Street, Suzhou Industrial Park
Suzhou Micro Flow Nano Biotechnology Co., Ltd
Process optimization of preparing highly stable nanosuspensions using the BEE homogenization mechanism in the United States
Date: 2025-11-14Read: 0
Nanosuspensions have become a hot topic in the development of new formulations due to their ability to significantly improve the solubility and bioavailability of poorly soluble drugs. ButBEE homogenizer from the United StatesWith its precise pressure control, efficient energy transfer, and excellent repeatability, it is widely used in the preparation of nanosuspensions. However, in order to obtain nanoparticles with high stability and narrow particle size distribution, it is necessary to systematically optimize the homogenization process parameters.
Firstly, homogenization pressure is a key factor affecting particle size. Usually, the higher the pressure, the stronger the shear force and cavitation effect, and the more complete the particle breakage. However, excessive pressure may lead to increased equipment wear or drug degradation. Research has shown that most APIs can achieve ideal particle sizes within the range of 8000-30000 psi. Secondly, the number of cycles also needs to be balanced: although multiple cycles can further reduce particle size, they may cause crystal transformation or aggregation.
In addition, prescription composition is equally important. The selection and concentration of stabilizers (such as poloxamer, HPMC, or lecithin) directly affect the Zeta potential and steric hindrance effect of nanoparticles, thereby determining their long-term stability.BEE homogenizer from the United StatesSupport online cooling system, which can effectively control the heat generated by high pressure and avoid deactivation of thermosensitive drugs.
Process optimization also needs to be combined with the QbD (Quality by Design) concept, and the relationship between key process parameters (CPP) and key quality attributes (CQA) should be determined through the DoE (Experimental Design) method. For example, a certain antifungal drug nanosuspension can be cycled three times at 20000 psi, supplemented with 0.5% Poloxamer 188, to obtain a stable product with PDI<0.15 and no significant settling for 6 months.
In summary, the BEE homogenizer in the United States is not only an efficient equipment, but also a core tool for achieving industrial scaling up of nanosuspensions. Its process optimization directly determines product quality and clinical conversion success rate.